Wegovy Pill / Oral Semaglutide 25 mg (Weight Management)

The oral Wegovy pill — formally oral semaglutide 25 mg — represents one of the most significant pharmaceutical advances in obesity medicine in years: it delivers the same active molecule as the injectable Wegovy in a once-daily tablet, eliminating the barrier of self-injection for patients who fear needles or prefer pill-based therapy. Approved by the FDA on December 22, 2025, and commercially available from January 2026, it is the first oral GLP-1 receptor agonist approved specifically for weight management in adults with obesity or overweight with at least one comorbidity. The OASIS 4 Phase 3 trial demonstrated that oral semaglutide 25 mg, taken once daily alongside a reduced-calorie diet and increased physical activity, produced an average weight loss of 16.6% among adherent participants — essentially matching the efficacy of injectable Wegovy in those who remained on treatment. The full population analysis (including those who discontinued) showed approximately 14% average weight loss. One-third of adherent participants achieved 20% or greater weight loss, compared to under 3% with placebo. Oral semaglutide does have one notable compliance requirement: the tablet must be taken on an empty stomach (fasting for at least 6 hours), with no more than 120 mL (4 oz) of plain water, and no food or drink for at least 30 minutes after ingestion. This is because GLP-1 peptides are poorly absorbed when co-ingested with food, and the tablet uses a proprietary absorption enhancer (SNAC — sodium N-[8-(2-hydroxybenzoyl)aminocaprylate]) to protect semaglutide from gastric digestion. This dosing protocol is stricter than the competitor oral GLP-1, Foundayo (orforglipron), which can be taken at any time without food restrictions — a practical distinction worth noting for patients with busy morning routines. List price is set at approximately $499 per month, with Novo Nordisk expected to offer savings programs. The oral formulation also carries the cardiovascular risk-reduction indication in adults with established CVD that was approved alongside the weight-loss NDA.